Clinical Trials Browser

Has results × Lymphoma × daratumumab × Clear all

NCT02927925 2021-01-14

A Study to Assess the Clinical Efficacy and Safety of Daratumumab in Participants With Relapsed or Refractory Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type

Phase 2 Completed

32 enrolled 17 charts

Lymphoma